1990-2023年全球心肌炎及其所致心衰负担分析
基于GBD 2023数据,估计1990至2023年全球心肌炎患病率、发病率、DALY、死亡率及死亡-发病比。2023年全球年龄标化患病率为4.84/10万,发病率12.46/10万,DALY率8.41/10万,死亡率0.21/10万。年龄标化DALY和死亡率分别下降62.48%和60.00%,但发病绝对数增加54.28%。
要点
- 全球年龄标化DALY和死亡率显著下降,但发病和患病率保持稳定。
- 发病绝对数从0.67百万增至1.04百万,增幅54.28%。
- 心肌炎所致心衰年龄标化患病率从2.33/10万降至1.76/10万。
核心结论
- 1990至2023年全球心肌炎年龄标化DALY和死亡率下降,但发病和患病率稳定,绝对负担因人口增长和老龄化而增加。
- 年龄组和社会人口指数分层间存在持续差异,需针对脆弱人群和低资源地区制定早期诊断策略。
研究设计与样本
- 基于GBD 2023研究,使用行政卫生机构和生命登记数据估计全球、区域和国家心肌炎负担。
- 按年龄、性别和社会人口指数五分位分层,估计患病率、发病率、DALY、死亡率和死亡-发病比。
- 采用基于模型的归因方法估计心肌炎所致心力衰竭的患病率。
主要发现
- 2023年全球年龄标化患病率4.84/10万(95%UI 3.98-5.80),发病率12.46/10万(95%UI 9.86-15.70)。
- 2023年全球年龄标化DALY率8.41/10万(95%UI 5.63-12.59),死亡率0.21/10万(95%UI 0.14-0.29)。
- 1990至2023年发病绝对数从0.67百万(95%UI 0.52-0.85百万)增至1.04百万(95%UI 0.83-1.32百万),增幅54.28%。
- 年龄标化DALY和死亡率分别下降62.48%和60.00%;死亡-发病比从1990年2.33降至2023年1.30。
- 2023年心肌炎所致心衰年龄标化患病率1.76/10万(95%UI 1.41-2.29),低于1990年的2.33/10万(95%UI 1.90-2.90)。
临床怎么用
- 临床应关注心肌炎绝对负担增加及年轻和老年人群的较高死亡-发病比。
- 在高资源地区患病率较高,但低资源地区死亡率下降幅度相似,需针对性改善早期诊断。
局限性
- 结果需结合诊断和编码实践的变化进行解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of recent trends in the burden of myocarditis has not been reported in detail. OBJECTIVES: This study aims to estimate the global, regional, and national burden of myocarditis from 1990 to 2023, using data from the GBD (Global Burden of Disease, Injuries, and Risk Factors Study) 2023. METHODS: As part of the GBD 2023, the authors used all available administrative health facility and vital registration data to estimate myocarditis prevalence, incidence, disability-adjusted life years (DALYs), mortality, and mortality-to-incidence ratio (MIR) for every country, stratified by age, sex, and quintiles of a Socio-demographic Index (SDI). The MIR represents the relative mortality burden compared with disease incidence at the population level. The prevalence of heart failure attributable to myocarditis was estimated using a model-based attribution approach. RESULTS: In 2023, the global age-standardized rates of prevalence, incidence, DALY, and mortality of myocarditis were 4.84 (95% uncertainty interval [UI]: 3.98-5.80), 12.46 (95% UI: 9.86-15.70), 8.41 (95% UI: 5.63-12.59) and 0.21 (95% UI: 0.14-0.29) per 100,000 population, respectively. Although global age-standardized prevalence and incidence rates remained stable from 1990 to 2023, the absolute number of incident cases increased by 54.28% from 0.67 million (95% UI: 0.52-0.85 million) to 1.04 million (95% UI: 0.83-1.32 million). Age-standardized DALYs and mortality rates decreased by 62.48% and 60.00%, respectively, over the same period. The MIR decreased across all age groups from 1990 to 2023 and remained highest among the youngest and oldest populations, with the ratio in those <5 years of age declining from 17.82% in 1990 to 6.32% in 2023. Across SDI strata, incidence rates remained stable from 1990 to 2023, while mortality rates declined in all quintiles and remained lowest in high SDI regions, whereas the MIR decreased from 2.33 in 1990 to 1.30 in 2023. In 2023, prevalence was highest in the high SDI quintile (6.30 [95% UI: 5.15-7.48] per 100,000 population) and lowest in the low-middle SDI quintile (4.10 [95% UI: 3.38-5.02]), reflecting disparities aligned with health resource availability. Age-standardized prevalence rates of heart failure attributable to myocarditis declined from 2.33 (95% UI: 1.90-2.90) per 100,000 population in 1990 to 1.76 (95% UI: 1.41-2.29) in 2023, with a U-shaped distribution across age groups showing the highest burden in those <5 years of age and >75 years of age in 2023. CONCLUSIONS: Although age-adjusted DALYs and mortality rates of myocarditis decreased globally from 1990 to 2023, incidence and prevalence remained stable, suggesting potential improvements in outcomes over time. However, absolute burden has grown due to population growth and aging, and important disparities persist across age groups and SDI strata. These findings highlight the need for targeted strategies to improve early diagnosis and reduce the burden of myocarditis, particularly in vulnerable populations and lower-resource settings, while being interpreted in the context of evolving diagnostic and coding practices.
引用
- Global, Regional, and National Burden of Myocarditis and Its Impairment, 1990-2023. J Am Coll Cardiol. 2026. PMID: 42684212. doi:10.1016/j.jacc.2026.07.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。